Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 50mg | $23.72 | $0.47/mg | In stock | Jul 8 |
| vial | 1250mg | $116.31 | $0.09/mg | In stock | Jul 8 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. GHK-Cu is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Sunrise Bioresearch sell GHK-Cu?
Yes — Sunrise Bioresearch currently lists GHK-Cu in 2 variants starting at $116.31 ($0.09/mg).
Is Sunrise Bioresearch's GHK-Cu third-party tested?
Yes — Disclosed Labs has indexed 7 Certificates of Analysis for Sunrise Bioresearch's GHK-Cu, with the most recent showing 99.6% purity. Sunrise Bioresearch holds an overall trust grade of A (93/100) across all 54 COAs on file.
What is Sunrise Bioresearch's trust grade for GHK-Cu?
Sunrise Bioresearch has an overall Disclosed Labs trust grade of A (93/100), computed from 54 COAs across all peptides. The most recent GHK-Cu COA was issued by ILS Labs.
Where is the cheapest GHK-Cu?
As of the latest data, Peptide Supply Co. offers GHK-Cu at $0.28/mg — compare with Sunrise Bioresearch's listing at $0.09/mg. See the full GHK-Cu price comparison.
Is GHK-Cu legal to buy?
GHK-Cu is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
| GHK100MAY26-01 | May 2026 | 99.1% | ILS Labs | Endotoxin, Sterility, Heavy metals | Confirmed1 flag | View |
| GHKSEP25-01 | Sep 2025 | 100.0% | Freedom Diagnostics | — | Confirmed | View |
| GHKAUG25-02 | Aug 2025 | 99.9% | Freedom Diagnostics | — | Confirmed | View |
| GHKAUG25-01 | Aug 2025 | 99.8% | Freedom Diagnostics | — | Confirmed | View |
| GHKNOV25-01 | — | 99.3% | Freedom Diagnostics | Endotoxin | Confirmed1 flag | View |
| GHK100FEB26-01 | — | 99.7% | Freedom Diagnostics | Endotoxin | Confirmed | View |
Disclosed Labs